MX2018001905A - Metodos para el tratamiento del virus de hepatitis c (vhc). - Google Patents
Metodos para el tratamiento del virus de hepatitis c (vhc).Info
- Publication number
- MX2018001905A MX2018001905A MX2018001905A MX2018001905A MX2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A MX 2018001905 A MX2018001905 A MX 2018001905A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- weeks
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención presenta terapias exentas de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es a lo largo de una duración más corta de tratamiento, tal como no mayor de 12 semanas. En un aspecto, el tratamiento comprende la administración de al menos dos agentes antivíricos de acción directa a un sujeto con infección por el VHC, en donde el tratamiento tiene una duración de 12 semanas y no incluye la administración de interferón o de ribavirina, y dichos al menos dos agentes antivíricos de acción directa comprenden (a) el compuesto 1 o una de sus sales farmacéuticamente aceptables y (b) el compuesto 2 o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/431,906 US11484534B2 (en) | 2013-03-14 | 2017-02-14 | Methods for treating HCV |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001905A true MX2018001905A (es) | 2018-11-09 |
Family
ID=61192811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001905A MX2018001905A (es) | 2017-02-14 | 2018-02-14 | Metodos para el tratamiento del virus de hepatitis c (vhc). |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3360555A1 (es) |
JP (1) | JP2018131439A (es) |
CN (1) | CN108421029A (es) |
AU (1) | AU2018201011A1 (es) |
BR (1) | BR102018002956A2 (es) |
CA (1) | CA2994496A1 (es) |
MX (1) | MX2018001905A (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1742913A1 (en) * | 2003-12-11 | 2007-01-17 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
KR101990279B1 (ko) | 2010-09-21 | 2019-06-19 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 hcv 세린 프로테아제 억제제 |
CN104383541A (zh) * | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
US20140274934A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Methods for treating hcv |
NZ719137A (en) * | 2013-03-14 | 2017-11-24 | Abbvie Inc | Combination of two antivirals for treating hepatitis c |
AU2015240754B2 (en) * | 2014-04-02 | 2020-06-25 | Abbvie Inc. | Methods for treating HCV |
JP6808660B2 (ja) * | 2015-07-08 | 2021-01-06 | アッヴィ・インコーポレイテッド | Hcvを処置するための方法 |
-
2018
- 2018-02-09 CA CA2994496A patent/CA2994496A1/en active Pending
- 2018-02-09 JP JP2018021874A patent/JP2018131439A/ja active Pending
- 2018-02-12 EP EP18156337.0A patent/EP3360555A1/en not_active Withdrawn
- 2018-02-12 AU AU2018201011A patent/AU2018201011A1/en not_active Abandoned
- 2018-02-13 CN CN201810149405.XA patent/CN108421029A/zh active Pending
- 2018-02-14 MX MX2018001905A patent/MX2018001905A/es unknown
- 2018-02-15 BR BR102018002956A patent/BR102018002956A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN108421029A (zh) | 2018-08-21 |
CA2994496A1 (en) | 2018-08-14 |
JP2018131439A (ja) | 2018-08-23 |
BR102018002956A2 (pt) | 2018-10-30 |
EP3360555A1 (en) | 2018-08-15 |
AU2018201011A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
PH12020550065A1 (en) | Hepatitis b antiviral agents | |
MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
RU2015114543A (ru) | Способы лечения гепатита с | |
MX2021002147A (es) | Tratamiento de la infección por virus de la hepatitis delta con interferón lambda. | |
MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
RU2015114566A (ru) | Способы лечения гепатита с | |
MX2020001422A (es) | Metodos para el tratamiento de hcv. | |
MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
AU2019384793A8 (en) | Methods for treating acute HCV | |
NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
MX2018000213A (es) | Metodos para tratar el vhc. | |
UA101772U (uk) | Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки | |
RU2008142658A (ru) | Способ лечения инфекционных поражений нервной системы | |
ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc |